NDAORALTABLET
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUCLADIN-S (buclizine hydrochloride) is an oral antihistamine tablet approved in 1957 for the treatment of nausea, vomiting, and motion sickness. Buclizine is a first-generation H1-receptor antagonist that crosses the blood-brain barrier to suppress signals in the chemoreceptor trigger zone and vomiting center. The exact mechanism of action in preventing emesis remains incompletely characterized but is consistent with central antihistaminergic activity.
LOE Approaching
This mature product is approaching loss of exclusivity with minimal commercial investment; teams are typically small and focused on defending market share rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BUCLADIN-S offers limited career growth due to its LOE-approaching lifecycle stage and minimal linked job openings (0 current roles). Roles tend to focus on lifecycle management, regulatory compliance, and defensive market positioning rather than innovation or expansion. Working on this product is best suited to early-career professionals seeking foundational commercial experience or specialists in legacy product management.
Brand Manager
Worked on BUCLADIN-S at Stuart Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.